AstraZeneca scores 52/100 (Making progress) on SINK's independent climate assessment — scored from public data only, no company payment can change a number. Last verified May 2026.
That places AstraZeneca joint 99th of 809 companies scored, and 2nd of 15 in Healthcare / Pharmaceuticals.
AstraZeneca has cut operational emissions 77.5% since 2015 and locked in science-based net-zero targets, but absolute supply chain emissions are rising 18.6% from baseline. Operations excel; supply chain and delivery risk on Scope 3 are the dominant weaknesses. Trade association memberships undermine climate advocacy clarity.
Every supplier scored from public evidence like this, ranked, in 48 hours. No questionnaires, and your suppliers never know.
This score uses public evidence only. Challenge any question for free, or ask for a human review of evidence you haven't published.
Same ten questions for every company. No private weighting.
SINK = (0.3 × Base + 0.7 × Performance) × ScaleStrongest on Carbon Footprint — Operations and Energy Source (9/10, 9/10). Weakest on Emissions Trajectory and Resource Use & Waste (4/10, 6/10).
12 sources used in this assessment. All publicly available. Each row shows which rubric questions it informed.
If you believe a source has been misread or a newer version exists, submit a challenge.
Where AstraZeneca sits among healthcare / pharmaceuticals peers.
Among the 15 major healthcare / pharmaceuticals brands we've scored, AstraZeneca sits 2nd of 15.
Score history begins 4 April 2026.
As AstraZeneca's score updates, the trajectory will appear here.
This score is not currently being contested.
Every challenge is published. We'd rather be corrected than wrong — that's the whole point.
No challenges submitted yet. If you have evidence that contradicts this score, you can challenge any question above — cite a public source and we'll review it.
AstraZeneca is a British-Swedish pharmaceutical company headquartered in Cambridge, UK, founded in 1913. With 70,600 employees and $24.4B FY2019 revenue, it ranks among the world's largest research-driven drugmakers, operating across oncology, cardiovascular, and respiratory therapy segments.
Peer pharma with similar SBTi net-zero targets and Scope 3 supply chain complexity
View breakdown →Comparable pharmaceutical scale; broader nature-positive and water stewardship programmes
View breakdown →Swiss-listed pharma with aggressive renewable energy and API pollution control initiatives
View breakdown →Renewable energy partner model; demonstrates credible net-zero transition pathway execution
View breakdown →Email alerts when a rubric question is verified, a challenge is resolved, or the overall score changes.
One email, every Sunday. Score changes, new research, the stories behind the numbers. Free.
No spam. Unsubscribe in one click.
Checking a company?
Search free →Checking your suppliers?
Get your list scored in 48 hours →Been scored?
See what's behind your number →Nobody can pay us to change a number.